A Pilot Study of Exercise in Patients With Docetaxel-Based Chemotherapy for Hormone Refractory Prostate Cancer

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00271687

Enrollment

Registered

2006-01-04

Start date

2006-02-28

Completion date

2007-11-30

Last updated

2016-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neoplasm Metastasis, Palliative Care, Prostatic Neoplasms

Keywords

exercise, exercise therapy, activities of daily living, quality of life

Brief summary

This study aims to provide preliminary data on the feasibility and outcomes of a 12 week exercise program on the quality of life of men with hormone refractory prostate cancer receiving docetaxel-based chemotherapy.

Interventions

BEHAVIORALExercise training

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

MALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* diagnosis of prostate cancer * receiving docetaxel-based chemotherapy at the CCI * age 18 years or over * approval of oncologist * informed written consent

Exclusion criteria

* life expectancy less than 6 months * Karnofsky performance score less than 70 * contraindications for exercise (e.g. uncontrolled cardiac, respiratory, hypertensive or psychiatric disorder) * unable to understand, read, write and speak English * unable or unwilling to attend supervised exercise sessions 3 times weekly * unable or unwilling to complete outcome assessments

Design outcomes

Primary

Measure	Time frame
feasibility (recruitment, adherence, safety)	—

Secondary

Measure	Time frame
quality of life	—
functional abilities	—

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026